Uncategorized

New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology

by Business Wire • 2021/04/16 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.

← New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) →

Post navigation